Asset Management Systems #asset #management, #bonds, #fund #management, #hedge #funds, #inventory, #investment #management, #mutual #funds,

Posted On Aug 8 2017 by

# Asset Management Systems Frequently Asked Questions Finding an asset management system In today’s complex and constantly changing environment investment managers need asset management systems that can meet the demands of a modern investment portfolio. Choosing effective asset software can mean the difference between an average investment portfolio and one that generates a significant amount of money. And this is even truer in unpredictable economies where the value of a single investment can fluctuate considerably. Financial asset management provides a way for investors to realise the full potential of their investments, showing them the risks and costs of the choices …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #small #pharma #companies

Posted On Aug 2 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharma #packaging

Posted On Jul 23 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #merk #pharma

Posted On Jul 9 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #biotech #jobs

Posted On Jul 4 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #cro #pharma

Posted On Jun 14 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharmaceutical #wholesalers

Posted On May 30 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Pharmaceutical Products Portfolio #digital #pharma

Posted On May 18 2017 by

#pharmaceutical products # Products TARGETED PORTFOLIO A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world. Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company …


Pharmaceutical Products Portfolio #global #pharma

Posted On May 2 2017 by

#pharmaceutical products # Products TARGETED PORTFOLIO A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world. Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company …


Pharmaceutical Products Portfolio #leading #pharmaceutical #companies #2013

Posted On Mar 25 2017 by

#pharmaceutical products # Products TARGETED PORTFOLIO A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world. Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company …